Comparing glucose monitors and a blood sugar test for diabetes in cystic fibrosis
Compares a wearable glucose monitor with a standard test for diabetes in cystic fibrosis.
Key facts
- Who runs it
- Medical College of Wisconsin
- Where
- Milwaukee, United StatesSee the site
- Trial code
- Registry title
- Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis
- Status
- Recruiting
- People taking part
- 30 people, planned
- Started
- 13 Jan 2025
- Expected to end
- 30 Sept 2027
- Type of study
- Observational
- Treatments tested
- Access to Dexcom G7 CGM Data
- Record updated
- 31 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cystic fibrosis who have normal or impaired glucose tolerance on a 2024 OGTT. It compares a continuous glucose monitor with the OGTT for diabetes screening.
- Age
- 18 years and older (adults)
- Sex
- All sexes can join.
- Disease stage
- Adults with cystic fibrosis and normal or impaired glucose tolerance on an OGTT completed in 2024. Not diagnosed with cystic fibrosis related diabetes (CFRD) on diabetes-causing medicines.
- Earlier treatment
- People with CFRD who are treated with diabetogenic medications cannot join. People who had a transplant cannot join.
- Biomarker or test result
- Normal glucose tolerance or impaired glucose tolerance on an OGTT done in 2024.
Main reasons for not taking part
- Diagnosed with CFRD and treated with diabetogenic medications
- Had a transplant
- Pregnancy
- Did not wear the CGM for the full 10 days
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- An adult patient, diagnosed with CF, established with Froedtert Multidisciplinary CF Clinic
- Normal glucose tolerance or impaired glucose tolerance per OGTT completed in 2024
- At healthy baseline status at time of CGM wear and OGTT
Who cannot take part
- Diagnosed with CFRD and treating with diabetogenic medications
- s/p transplant
- failure to wear CGM for entirety of 10 days
- pregnancy
Where in United States
- The Medical College of WisconsinMilwaukee, United StatesContact: Julie Biller, MDTaking people
About the trial
What the trial wants to find out
Cystic Fibrosis (CF) related diabetes (CFRD) is a unique form of diabetes mellitus, different from type 1 diabetes and type 2 diabetes. The diagnosis of CFRD is associated with a decline in pulmonary function, decreased nutritional status, and increased mortality. CFRD is extremely common in people with CF, occurring in approximately 40-50% of adults with CF. Impaired glucose tolerance or dysglycemia is also very common in CF. It is standard of care to screen for CFRD annually from the age of 10 years with a two-hour Oral Glucose Tolerance Test (OGTT) with 75 g dextrose. The gold standard screening for CFRD is the OGTT which is problematic as it is time consuming for patient and staff and adherence to annual screening is low among CF centers.
Read full original descriptionShow less
Survival has improved dramatically with the advent of CFTR modulators and it is presumed that the incidence of CFRD will increase with increased life expectancy. The Cystic Fibrosis Foundation (CFF) has developed the oldest disease specific patient registry, consisting of approximately 35000 patients, so there is vast historical information available on individual patients and larger datasets on the CF community as a whole. Based on the 2021 CFF patient registry data, the current life expectancy for CF patients born between 2017 and 2021 is 53 years - a 15 year increase from a decade ago.
The group in the trial
- Cystic Fibrosis
Treatment: Access to Dexcom G7 CGM Data
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance
- Plain-language title
- Comparing glucose monitors and a blood sugar test for diabetes in cystic fibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 31 July 2026